This week's StoxEurope deep-dive takes UCB SA/NV (UCB, Euronext Brussels) — a Belgian biopharmaceutical — through the triangulation method. It is the first deep-dive in the series where the selection rules leave a single intrinsic model standing.
The two models that switched off did so for opposite reasons. UCB pays out 17,7 % of basic earnings, far below the 40 % at which a dividend stream can carry a valuation, so the dividend discount model is out. And at roughly 3,9× book value, above the 3× line, the residual income model is out too — UCB's value sits in intellectual property and pipeline, not on the balance sheet. That leaves the discounted cash flow alone, and it changes what this article can claim.
One of three intrinsic models applies, so there is no Confluence Zone — zone reporting is suspended under the interim methodology rules, and with one model none could form in any case. No consolidated fair value is offered.
Marrket Cross-Check (Sanofi, Novartis, AstraZeneca): EV/EBITDA €181,32 · Relative €180,77 — load-bearing here, reported beside the DCF, never folded into it.
The price is €221,30 (as at 30 July 2026), above the DCF estimate and above both peer readings, but well inside the sensitivity range. Two numbers worth stating plainly: 77 % of the DCF's value sits in the terminal value, and the WACC-minus-growth spread is 5,84 %. A model with three-quarters of its answer beyond year five is a model whose long-run assumptions are doing the work.
Please view the detailed vaulation at : https://stoxeurope.com/valuation/ucb/
Disclosures
Position disclosure: The author holds a position in UCB SA/NV as at 30 July 2026. This valuation is a StoxEurope opinion, based on honest research. Mistakes are possible.
This article demonstrates a valuation methodology. It is not an investment recommendation, is not personalised to any reader's circumstances, and every figure in it depends entirely on the stated assumptions. Do your own research.
Have other thoughts on UCB?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
The user StoxEurope has a position in ENXTBR:UCB. Simply Wall St has no position in any of the companies mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The author of this narrative is not affiliated with, nor authorised by Simply Wall St as a sub-authorised representative. This narrative is general in nature and explores scenarios and estimates created by the author. The narrative does not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company's future performance and are exploratory in the ideas they cover. The fair value estimates are estimations only, and does not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that the author's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
